Today: December 18, 2018, 2:47 pm

Aytu BioScience Announces Commercial Availability of Tuzistra(R) XR 2018-12-06 14:06:35
Nationwide availability for the first and only codeine-based, extended-release, oral-suspension cough/cold treatment in U.S.

ENGLEWOOD, CO / ACCESSWIRE / December 6, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the commercial availability of Tuzistra® XR (codeine polistirex and chlorpheniramine polistirex) oral suspension, CIII. Aytu BioScience previously announced the Company's commercial license to Tuzistra XR and a complementary antitussive pending FDA approval on November 5, 2018 and has now shipped initial Tuzistra XR product supply to U.S. wholesalers for availability to retail pharmacies throughout the U.S.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, ''We are pleased to have Tuzistra XR available now to customers in the U.S. as we enter the peak months of the annual cough and cold season. Tuzistra XR is a novel, important therapeutic option for the treatment of cough and associated upper respiratory symptoms as the only 12-hour, codeine-based antitussive suspension. Aytu looks forward to working with physicians, pharmacies, and other healthcare professionals in sharing Tuzistra XR's clinical benefits and informing clinicians about the Company's patient access programs designed to assist Tuzistra XR patients with co-pay assistance and reimbursement support.''

Tuzistra XR is a patented combination of codeine, an opiate agonist antitussive, and chlorpheniramine, a histamine-1 receptor antagonist, indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults aged 18 years and older. Tuzistra XR is protected by two Orange Book-listed patents extending to 2031 and multiple pending patents.

According to MediMedia, the US cough cold prescription market is worth in excess of $3 billion at current brand pricing, with 30-35 million annual prescriptions. This market is dominated by short-acting treatments, which require dosing 4-6 times a day. Tuzistra XR was developed using Tris Pharma's liquid sustained release technology, LiquiXR®, which allows for extended drug delivery throughout a 12-hour dosing period.



TUZISTRA XR is a combination of codeine, an opiate agonist antitussive, and chlorpheniramine, a histamine-1 (H1) receptor antagonist indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold.

Limitation of Use: Not indicated for pediatric patients under 18 years of age.




Ultra-Rapid Metabolism

Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.

Concomitant Use with Benzodiazepines, CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.


Postoperative pain management of children undergoing tonsillectomy and/or adenoidectomy.

Patients with known hypersensitivity to codeine, chlorpheniramine, or any of the product components of TUZISTRA XR.


Risk of death in individuals who are ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death. Some individuals CYP2D6 genotype, which prevalence varies widely, and is estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs.

Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Dose-related respiratory depression: Use with caution, including when used postoperatively, in patients with pulmonary disease or shortness of breath, or whenever ventilator function is depressed. Overdose of codeine in adults has been associated with fatal respiratory depression, and the use of codeine in children, have been associated with fatal respiratory depression. If respiratory depression occurs, discontinue the drug and use naloxone hydrochloride or other supportive measures as necessary.

Drug dependence: Prescribe with caution that is appropriate to the use of other opioids.

Head injury and increased intracranial pressure: Avoid in patients with head injury, intra-cranial lesions, or increased intracranial pressure.

Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating heavy machinery. Avoid concurrent use of alcohol or other central nervous system depressants.

Obstructive bowel disease: Chronic use of opioids, including codeine, may result in constipation or chronic obstructive bowel disease, especially in patients with underlying intestinal motility disorders.

Acute abdominal conditions: Use with caution in patients with acute abdominal conditions.

Dosing: Measure dose with an accurate milliliter measuring device; a household teaspoon is not accurate and could lead to over dosage, resulting in serious adverse reactions.

Special risk patients: Caution in elderly patients and those with asthma, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture.


Common adverse reactions of TUZISTRA XR include: nausea and vomiting, constipation, abdominal distension, abdominal pain, blurred vision, diplopia, visual disturbances, confusion, dizziness, depression, drowsiness, sedation, headache, euphoria, facial dyskinesia, feeling faint, light-headedness, general feeling of discomfort or illness, excitability, nervousness, agitation, restlessness, somnolence, insomnia, dyskinesia, irritability, tremor.

To report

Press Information

Published by
Fred Gautreau

# 870 Words
Related Articles
More From The Author
Riot Blockchain Enhances Profitability and Achieves Additional
Riot reduces mining costs by 24%; RiotX adds Georgia license CASTLE ROCK, CO / ACCESSWIRE / December 6 2018 / [..]
Premier Biomedical Signs Agreement With CBD HEMP [..]
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2018 / Premier Biomedical, Inc (OTC: BIEI) a research based publicly traded [..]
GreenBox POS Releases TrustEscrow to Production - [..]
SAN DIEGO, CA / ACCESSWIRE / December 6, 2018 / GreenBox POS, LLC ("GreenBox", "GRBX", the "Company") is [..]
Maxtech Initiates 2019 Vanadium Exploration Program in [..]
Notifies Ministère de l'Énergie et des Ressources Naturelles Focusing on Lac Patu Vanadium Project VANCOUVER, BC / ACCESSWIRE / [..]
RMS Medical Products Announces New Board Members
CHESTER, NY / ACCESSWIRE / December 6, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today [..]
More From Health
Over 2025, The Global HPMC Capsules Market [..]
HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in [..]
Indiva åbner vejen til det europæiske cannabismarked [..]
Aftalen omfatter en licens til 100% overtagelse af dyrkning og ekspedition af cannabis til medicinske formål under Lægemiddelstyrelsens udviklingsprogram. [..]
Breathe easy at home with Blueair’s revolutionary [..]
Dubai UAE, November 29, 2018: According to a recent report by the World Health Organisation (WHO) nine in ten people [..]
5 Growth Hacks to Increase Followers on [..]
22 November 2018 – Medium has posted an article in which there is a description of five important tips on [..]
Middle East Organic & Natural Products Expo [..]
The Middle East Organic & Natural Products Expo 2018 is returning to Dubai Convention & Exhibition Centre on November 18-20. [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.